Aug 24 (Reuters) - The European Commission on Thursday approved U.S. drugmaker Pfizer's (PFE.N) vaccine for respiratory syncytial virus (RSV) to protect both babies and older adults in the ...

Women may soon have a vaccine they can take during a pregnancy to help protect their newborn from respiratory syncytial virus ...

The European Medicines Agency (EMA) and the European Centre for Disease Control (ECDC) recommend targeting people at risk in ...

The way has been largely cleared for the rollout of Pfizer’s respiratory syncytial virus (RSV) vaccine to help protect ...

GSK announced on Monday that its vaccine, Arexvy, has received approval from Japan's Ministry of Health, Labour and Welfare ...

New Scientist explains how the latest covid-19 booster vaccines are different from previous ones, and who should get them ...

The new RSV shots are here, and while older adults and infants are already approved for them, the Centers For Disease Control and Prevention (CDC) are now recommending the vaccine to a new group.

In a nearly unanimous vote, advisors to the Centers for Disease Control and Prevention have recommended a new vaccine to ...

Updated COVID-19 vaccines are being rolled out in the U.S., aimed at targeting the latest, prevalent variants of the disease.

Pregnant people should get an RSV vaccine from Pfizer that transfers antibodies to their babies, according to a new CDC ...

(Alliance News) - GSK PLC on Monday said the Japan Ministry of Health, Labour & Welfare has approved Arexvy for adults over 60. Arexvy is a vaccine used for the prevention of respiratory syncytial ...

GSK plc (GSK, GSK.L) said Japan's Ministry of Health, Labour and Welfare has approved Arexvy for the prevention of respiratory ...